William Blair Sticks to Its Buy Rating for Cellectis SA (CLLS)


William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLS) today. The company’s shares opened today at $19.80.

Prasad wrote:

“We continue to see the potential for one or more potential readouts by year-end, which would be significant catalysts for the stock.”

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 21.9% and a 63.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.

Cellectis SA has an analyst consensus of Strong Buy, with a price target consensus of $42.75.

See today’s analyst top recommended stocks >>

Based on Cellectis SA’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.98 million. In comparison, last year the company had a GAAP net loss of $25.49 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts